共查询到15条相似文献,搜索用时 218 毫秒
1.
2.
3.
4.
5.
日本版NIH及其制药企业,政策制定·战略规划需要佐证。本研究尝试基于新的指标体系对制药行业现状进行俯瞰与预测未来。连载第四篇,为了基于专利把握医药品产业的基础研究能力,定位与制药企业各个研发项目的进展状况【临床前实验】→【Ⅰ期临床试验】→【Ⅱ期临床试验】→【Ⅲ期临床试验】→【批准申请】→【批准】→【上市】密切相关的专利,尝试导出其新型指标。明确了作为指标,IPC分类、被引专利数、专利引用非专利文献数有效。基于专利的这些新指标,不但是通过在研药物(pipeline),也可以通过专利把握医药品产业新药创出力以及未来新药的创出力。 相似文献
6.
7.
8.
9.
对专利组合理论进行介绍,构建基于技术生命周期的专利组合判别模型,并以抗HBV制药企业为实证研究对象,利用Logistic模型生成S曲线进行技术生命周期判断。在此基础上,绘制技术生命周期与专利指标相结合的组合判断图,从而辅助组织监测竞争对手的相对专利地位和认识技术领域的发展优势。 相似文献
10.
11.
科学技术类博物馆通过构建一个适合自身发展的研发创新体系,能够有效提升其创新能力,实现高质量发展。研发创新体系由创新内生动力系统、创新资源组织系统、创新体系开放系统、创新成果反馈系统组成。这四个子系统相互影响、相互支撑,不断在体系内部发生作用并与体系外部交换能量,使研发创新体系的运作形成正螺旋,从而推动博物馆研发创新能力的提升。 相似文献
12.
In this paper we use scale-independent indicators to explore the performance of the Chinese innovation system from an economic and from a science and technology point of view, and compare it with 21 other nations. Some important developments in the Chinese innovation system, hidden by rankings by conventional performance indicators, were revealed. We find that gross domestic expenditure on R&D (GERD) & gross domestic product (GDP) and GDP & POP (population) all exhibit strong ‘Matthew effects’, measured by their scaling factors. This means that the Chinese R&D intensity (GERD/GDP) and national wealth (GDP per capita) are growing significantly with the increase of the GDP. Also pairs such as citations & papers, papers & GDP, citations & GDP, and paper & GERD exhibit these ‘Matthew effects’. This observation points to the fact that in China scientific outputs and impacts are growing faster than economic growth and research investment. However, according to another scale-independent indicator, namely the adjusted relative citation impact (ARCI), China ranks on the bottom of the list, but the growth rate of the ARCI is the highest among these countries (comparing the periods 1995–1999 and 2001–2005). To sum up, we interpret these findings to mean that the scientific outputs and impacts of China show a real tendency of catching up with its economic growth. It is expected that with an increase of its GDP and R&D intensity China will show a sustained increase in indicators related to science and technology. Similarly, there are very strong ‘Matthew effects’ between the outputs of technology (patents) and economic growth and research investment. This means that the outputs of technology are expected to increase considerably with an increase of GDP and R&D expenditure. Furthermore, in the Chinese innovation system the government intramural expenditure on R&D (GOVERD) has a stronger non-linear impact on patent productivity than business enterprise expenditure on R&D (BERD). This shows that in China research institutions financed by the government play a more important role than enterprises. 相似文献
13.
R&D 经费、科技投入及政策定位的思考 总被引:1,自引:0,他引:1
丁厚德 《中国科技资源导刊 (中国信息导报)》2012,(1):2-10
R&D 资金投入是最重要的科技经费投入,在我国经历了不同政策定位的发展过程。20 世纪90 年代国家
高层决策, 要加大科技投入,并规定了R&D 资金投入的指标,经过18 年的努力,才达到原定10 年要实现的愿望。文
章在分析我国R&D 资金投入经历的政策定位的基础上,对增加R&D 经费投入进行思考,提出了一些想法。 相似文献
14.
万里鹏 《中国科技资源导刊 (中国信息导报)》2011,(4):15-22
文章通过统计重庆市专利申请和R&D 相关数据,在分析其发展趋势的基础上,运用SPSS 软件对专利申请
量和R&D 指标作相关性分析并建立回归模型。结果显示:专利申请量与R&D 支出呈显著正相关关系,政府、企业应
继续加大R&D 投入力度,尤其要发挥企业的主导作用。 相似文献
15.
何涌 《中国科技资源导刊 (中国信息导报)》2011,(4):12-14
企业R&D 不仅是企业产品生命周期的一个阶段,而且贯穿整个产品生命周期,而R&D 资金合理配置是研发
这一资本密集型活动取得成果的根本保证。文章研究了企业R&D 资金配置在产品生命周期的时序分布模式,揭示基于产
品生命周期的R&D 资金配置规律,为企业增强R&D 资金管理能力,提高技术创新能力提供依据。 相似文献